The German medical technology industry generates annual revenue of €41.4 billion, employs approximately 210,000 people, and has an export share of 68 percent. According to the SPECTARIS Medical Technology Yearbook 2026 , this makes Germany the leader in Europe and one of the top three medical technology hubs worldwide. However, the reality behind these figures is more nuanced than the strength of exports might suggest at first glance. Never before has the technological potential offered by artificial intelligence, robotics, and digital platforms been greater. And never before has regulatory pressure on small and medium-sized manufacturers reached a level that management feels on a daily basis.
Structurally, the industry is characterized by small and medium-sized enterprises. About 93 percent of companies are small and medium-sized businesses, many of which are global market leaders in highly specialized niche segments; they have been owner-managed for decades and, with an average R&D expenditure of 9.2 percent of revenue, are significantly more innovative than the industrial average. The fact that these companies continue to invest despite all the challenges is no coincidence: AI-supported diagnostics, telemonitoring, and autonomous surgical assistance are no longer niche topics but are now part of product development across the entire industry. The yearbook estimates that new digital offerings alone will generate an additional revenue potential of around €15 billion within the industry by 2028.
On the other hand, there is a regulatory burden, the exact extent of which is revealed by the BVMed Fall Survey 2025 , which surveyed 116 companies. Eighty percent cite bureaucratic red tape as the most significant cost driver, while 65 percent point to the increased certification costs resulting from the EU Medical Devices Regulation. The bottom line is sobering: While many companies expect revenue growth, more than half also anticipate declining profits. As a result, 31 percent are shifting investments abroad, and 22 percent are reducing their overall investments in Germany. The fact that 56 percent of BVMed members now prefer the U.S. FDA system to the European regulatory framework makes the prevailing sentiment abundantly clear. The German federal government has launched the High-Tech Agenda for Germany (HTAD) in May 2026, the federal government explicitly designated medical technology as a key technology and announced an interagency strategy with concrete legislative measures for the summer of 2026. It remains to be seen whether and how quickly this will have an effect.
For entrepreneurs looking to determine the right time for a succession or sale, the current market environment is more attractive than many might expect. Strategic acquirers from Germany and abroad, financial investors, and pharmaceutical companies are actively seeking out specialized companies with proprietary technologies and growth potential in the digital health sector. Specialized medical devices promise shorter development cycles and more attractive margins than many other industrial sectors. Regulatory burdens that put pressure on profits in the short term have little impact on the strategic attractiveness of such companies, as long as their technological foundation and customer relationships remain intact. Anyone who initiates a structured process today will encounter a pool of buyers that is both active and well-capitalized.
In recent years, Albia Capital has advised several companies in the medical technology and healthcare sectors on their sales. Through these projects, we have gained firsthand, practical knowledge of the industry-specific requirements—ranging from the regulatory nuances of the EU MDR to valuation issues in a certification-intensive environment, and the personal considerations that owners must weigh in such processes.
Please feel free to contact us at any time—with no obligation and, of course, in complete confidence—if you would like to discuss this in more detail.
